Resverlogix Corp.'s Profile
Resverlogix Corp. (TSX: RVX) is developing apabetalone (RVX-208), a first-in-class, small molecule selective BET bromodomain inhibitor. Apabetalone is the only selective BET bromodomain inhibitor in clinical trials. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. Apabetalone is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, Orphan diseases (PNH), and Alzheimer's disease, while maintaining a well described safety profile. Resverlogix has commenced a Phase 3 clinical trial in CVD patients with type 2 DM and low HDL, with a primary endpoint of time to first occurrence of Major Adverse Cardiac Events (MACE).
Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.
Management & Directors
-
DONALD J. MCCAFFREY
President and CEO, Co-FounderDonald McCaffrey is President & Chief Executive Officer (CEO) of Resverlogix Corp. He has over 35 years of business experience including 15 years of drug discovery & development. Donald has led Resverlogix through significant changes and achievements from its initial days as a private company to becoming a TSX listed company. He has personally raised over $300 million for research and clinical development in the areas of cardiovascular disease, diabetes mellitus, chronic kidney disease, Orphan diseases, Alzheimer’s disease and other serious indications. In addition to garnering appropriate financing for Resverlogix’s aggressive development plan, Donald has strategically directed the company in its continued partnering discussions with global pharmaceutical companies, establishing one of the largest China biotech partnerships to date with Hepalink Pharmaceuticals.
Donald’s expertise in corporate operations has attracted an international team of experts in research, development, and corporate affairs to Resverlogix. Lead drug, apabetalone (RVX-208) has now commenced a Phase 3 clinical trial called 'BETonMACE.' Apabetalone is a regulated drug which has the potential to be first in a new class of drugs for the reduction in Major Adverse Cardiac Events (MACE).
As President and CEO of Resverlogix, Mr. McCaffrey spearheaded the development and spin-out of Resverlogix’s subsidiary RVX Therapeutics Inc. to Zenith Epigenetics Corp.. Zenith Epigenetics is developing bromodomain (BET) inhibitors (BRD4) for the treatment of cancer and autoimmune disorders and has an estimated enterprise value of $100 million. Mr. McCaffrey is the current President and CEO of Zenith Epigenetics and has assembled a world class Oncology team to further the development of this program. Mr. McCaffrey is also the Chairman of the Board of Directors for Zenith Epigenetics.
Donald’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year three times. Under Donald’s guidance, Resverlogix was honored with multiple awards, the most prestigious being the 2008 World Economic Forum (WEF) Technology Pioneer award in Davos Switzerland. He has also arranged support for several non-profit organizations, including the Libin Cardiovascular Institute of Alberta, Juvenile Diabetes Research Foundation, Sanofi Biogenius Canada (MindFuel), United Way, Mount Royal University Foundation, Alberta Children's Hospital, Edge School Foundation, Education Matters, Calgary Urban Project Society Literacy Program, Movember Foundation, and Enbridge Ride to Conquer Cancer.
-
DR. EWELINA KULIKOWSKI, PH.D.
Senior Vice President of Research & DevelopmentDr. Kulikowski has over 11 years experience in scientific research and drug development. Dr. Kulikowski joined Resverlogix in 2005 as Director of Research and Development and has been involved in the development of lead drug RVX-208 (apabetalone) from its discovery through to the IND and into clinical development. Dr. Kulikowski has led projects in oncology, ophthalmology, and vascular inflammation, as well as served as a liaison between the science and business teams. As Director of Business Development and Scientific Affairs, Dr Kulikowski was involved in various aspects of pipeline development including market, reimbursement and pharmacoeconomic surveys, regulatory affairs, commercial and lifecycle management. Most recently, Dr. Kulikowski has led the Neurodegenerative Program and continues to oversee this area of development. In 2004, she received her Doctorate in Oncology from the University of Calgary, AB.
-
DR. NORMAN C.W. WONG, M.D., FRCP
Chief Scientific Officer & Co-FounderDr. Wong's research interest focus is on the molecular actions of hormones related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus. His clinical interest encompasses patients with thyroid disease or diabetes mellitus. His most recent successes have come from elucidating the potential therapeutic opportunities for cardiovascular disease by harnessing the regulation of Apolipoprotein A-I (ApoA-I) gene expression.
Dr. Wong keeps active in the academic community with speaking engagements at national and international medical conferences. He has been the author and co-author of more than 275 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.
-
A. BRAD CANN, CA
Chief Financial OfficerBrad has more than 19 years of financial and business experience. Prior to joining Resverlogix, Brad was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust, a diversified hospitality trust engaged in hotel ownership, investment, management and franchising, and Canada's second largest hotel REIT. Brad joined Royal Host in January 2004 and held a number of senior positions and was appointed Chief Financial Officer in May 2007 and Executive Vice President in January 2008. Brad's responsibilities included financial reporting, accounting, taxation, investor relations, payroll, information technology and internal audit. As acting Co-Chief Executive Officer of Royal Host, Brad shared responsibility for developing the strategic initiatives of the Trust and leading its executive team in day-to-day operations, as well as investing, financing and real estate transactions.
Prior to joining Royal Host, Brad was a business consultant and held senior management positions with several companies including Chief Financial Officer of a sulphur export development company and Chief Financial Officer of an oilfield waste water treatment company. Prior thereto, Brad held various positions with a chartered accounting firm.
Brad is a Chartered Accountant and a Chartered Business Valuator, and holds a Bachelor of Commerce from the University of Saskatchewan.
-
DR. JAN O. JOHANSSON, M.D., PH.D.
Senior Vice President Medical AffairsDr. Johansson has had a distinguished 30 plus year career of which the past 18 years have been in small biotechnology and large pharmaceutical companies with expertise in the cardiovascular disease therapeutic area. He has served as Chief Medical Officer at Nuvelo, Inc., VP, Clinical Research and Development at Lipid Sciences, Inc. and was Co-founder, VP, Clinical Affairs and Senior Clinical Research Fellow of Esperion Therapeutics, Inc. From 1995 to 1997, Dr. Johansson was a medical adviser with executive responsibilities at Pharmacia bringing one lipid lowering product to the market and heading the apolipoproteinA-IMilano clinical program.
Dr. Johansson earned his M.D. and Ph.D. at the Karolinska Institute in Sweden where he lead a successful career as a tenured associate professor at the Karolinska Hospital and as a practicing physician. He has published more than 50 peer-review medical articles, and is a member of several scientific organizations including the American Heart Association and the European Atherosclerosis Society.
-
DR. MICHAEL SWEENEY, M.D.
Senior Vice President of Clinical DevelopmentDr. Sweeney, a cardiologist with extensive experience in pharmaceutical product development and marketing, will oversee clinical development programs for RVX-208 in cardiovascular disease (CVD), diabetes mellitus, and other indications.
Dr. Sweeney has an impressive career history, spanning over 26 years in the pharmaceutical industry. This includes 11 years at Pfizer Inc., holding a variety of senior-level medical and marketing positions, including Senior Director, Urology Global Medical Group Leader and Director of Marketing of the Viagra® Worldwide Team. Prior to joining Resverlogix, Dr. Sweeney was Chief Medical Officer and Vice President of Research and Development at Depomed, Inc. in Silicon Valley. Dr. Sweeney was also the Vice President of Medical Affairs at CV Therapeutics, Inc., where he built the medical affairs department to enable the successful launch of Ranexa® for patients with cardiovascular disease and chronic angina.
Dr. Sweeney holds biochemistry and medical degrees from Liverpool University and an advanced medical research degree from Manchester University in the U.K. Dr. Sweeney also holds post-graduate diplomas in pharmaceutical medicine and pharmaco-epidemiology from the University of London. He is a fellow of the Royal College of Physicians of Edinburgh.
-
KENNETH LEBIODA, BA
Senior Vice President Business & Corporate DevelopmentKen has over 25 years experience in the innovative pharmaceutical industry with leading global companies such as Bristol-Myers Squibb, Hoechst Marion Roussel and Marion Merrell Dow. He held a variety of management positions with these companies in the areas of sales and business development, regulatory affairs, reimbursement and market access. Ken's past contributions in helping build leading global cardiovascular brands such as Plavix, Pravachol, Cardizem, and Avapro will provide strategic guidance for the company's technologies in the areas of market analysis, regulatory affairs, pharmacoeconomics, licensing and commercial development.
-
DR. HENRIK C. HANSEN, PH.D.
Vice President of Intellectual PropertyHenrik C. Hansen joined Resverlogix in 2005 and currently holds the position of VP of Intellectual Property. Henrik has more than 13 years of experience, from both academia and industry, in basic research, drug discovery, and drug development. His areas of expertise include medicinal chemistry and carbohydrate chemistry, process development, and manufacturing of drug substances and drug products under cGMP for clinical use.
Henrik holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 40 articles and meeting abstracts and is listed as inventor of 9 patent families.
-
CLAYTON PARADIS
Vice President of Investor RelationsClayton brings 15 years of capital markets and investor relations experience to Resverlogix. Most recently, Clayton led the investor relations function for one of Canada’s largest energy companies with shareholders and joint venture partners geographically dispersed throughout North America, Europe and Asia. Prior to his career in investor relations, Clayton worked for two of Canada’s largest financial institutions in equity research as an energy specialist, one of which was a number one ranked Royalty Trust Research Team (Brendan Wood Survey 2005).
Clayton’s strengths lie in his ability to engage a community through effective communications, navigate complex systems and strategic transitioning. His efforts in investor relations have been recognized by industry and peers through recognition of being amongst the top five companies in Canada for the “Most Progress in Investor Relations” twice in his career in the IR Magazine Investor Perceptions Study.
Clayton is a member of the Canadian Investor Relations Institute (CIRI) and holds an MBA – Finance from the University of Calgary and Bachelor of Management from the University of Lethbridge.
Broker Fact Sheet
-
RVX Broker Fact Sheet
Thu Mar 29, 2019Fact sheet details
Company Links
-
Mon Jan 09 2017, 05:12PM
-
Thu Dec 15 2016, 01:44PM
-
Fri Oct 14 2016, 03:20PMFull set of 100 slides from Resverlogix R&D Update from 10/13/16 in NYC.
-
Tue Dec 20 2016, 10:35AMRenal Program Advancing; Financing Options Clarified
-
Wed Nov 09 2016, 05:13PMNovember 8, 2016, Resverlogix presented at BIO Europe in Cologne, Germany.
-
Wed Sep 21 2016, 01:22PMMaintaining CAD$5.00 Target: Awaiting First BETonMACE Futility Readout.
-
Thu Sep 01 2016, 09:30AMThis Data in Brief article is a comprehensive presentation of the gene expression and protein analysis done in human whole blood and human primary hepatocytes.
-
Thu Sep 01 2016, 09:24AMArticle in "Genetic Engineering & Biotechnology News" with a large focus on Resverlogix and Zenith
-
Mon Aug 01 2016, 11:46AM
-
Fri Jul 29 2016, 11:17AMHere is the Checklist for Management from 7/28/16 that was composed by members of the RVX Agoracom Hub. We will do our best to update this list quarterly.
-
Thu Jul 07 2016, 07:41PMOn the eBriefing page, click on "Media" to see the available slides/audio including talks from Resverlogix (Ewelina Kulikowski) and Zenith Epigenetics (Eric Campeau).
-
Thu Jun 30 2016, 10:09AM
-
Mon Jun 13 2016, 04:31PM
-
Mon Jun 13 2016, 01:33PMSlides from the Q2 2016 Corporate Update on 6/13/16.
-
Thu Jun 09 2016, 01:40PM
-
Thu Jun 09 2016, 01:39PMSlides from the Resverlogix presentation at BIO International 2016 on June 7, 2016 in San Francisco, CA
-
Thu May 12 2016, 11:14AMNew RVX research report 5/11/16 by Marcel Wijma, Van Leeuwenhoeck Institute.
-
Thu May 12 2016, 11:07AM
-
Wed Mar 30 2016, 04:06PMRVX at Richmond Club 3/23/16
-
Thu Jan 28 2016, 09:53AMLatest Seeking Alpha article by Bjarke Krysel Christensen originally published December 29, 2015
-
Sat Jan 23 2016, 11:51PMAn article entitled "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" was published by the Resverlogix team in the journal Atherosclerosis on January 22, 2016.
-
Tue Jan 19 2016, 05:08PMZacks Small Cap Research Digest from January 19, 2016
-
Wed Dec 16 2015, 12:52PM
-
Fri Nov 06 2015, 09:20PMZacks Small Cap Research Digest from November 3, 2015
-
Fri Nov 06 2015, 09:15PMRVX covered by Stonegate Capital...
-
Tue Oct 06 2015, 12:43AM...notes c/o fouremm...
-
Tue Oct 06 2015, 12:41AM...notes c/o masila...
-
Sat Oct 03 2015, 02:24AMResverlogix Corporate Update Tuesday September 29, 2015... transcript of webcast
-
Thu Sep 24 2015, 07:12AMOrphan Disease Program Announcement for Complement Mediated Diseases
-
Fri Sep 18 2015, 10:42AM
-
Thu Sep 17 2015, 02:02PMDon McCaffrey was recently interviewed by Stock News Now
-
Wed Sep 16 2015, 11:34PMSept. 10, 2015: Donald McCaffrey presented at the Rodman & Renshaw 17th Annual Global Investment Conference..
-
Mon Aug 31 2015, 09:39AMLife Science Report Interview with Don McCaffrey from 8/26/15
-
Mon Aug 31 2015, 09:36AMNews release following Dr. Norman Wong's presentation at the ESC 2015 meeting in London.
-
Tue Jul 21 2015, 10:03AM
-
Wed Jul 08 2015, 04:24PM
-
Wed Jul 01 2015, 09:43AM
-
Wed Jul 01 2015, 09:41AM
-
Tue Jun 30 2015, 09:17PM
-
Thu Jun 25 2015, 01:02PMResverlogix’s Dr. Ewelina Kulikowski has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.” The article focuses on how BET inhibition has an impact on multiple biologies with the potential to treat a variety of conditions such as cancer, inflammatory, neurodegenerative, metabolic and cardiovascular disorders.
-
Thu Jun 25 2015, 10:27AM
-
Mon Jun 22 2015, 10:34AM
-
Thu Jun 18 2015, 11:31AM
-
Tue Jun 09 2015, 11:33AM
-
Sun May 31 2015, 03:15PM
-
Fri May 29 2015, 08:36PM
-
Thu May 28 2015, 11:13PM
-
Wed May 20 2015, 08:49PM
-
Wed May 20 2015, 08:42PM
-
Wed May 20 2015, 08:35PM
-
Wed May 20 2015, 02:06PM
-
Wed May 20 2015, 02:04PM
-
Wed May 20 2015, 02:03PM
-
Wed May 20 2015, 02:00PM
-
Wed May 20 2015, 01:56PM
-
Wed May 20 2015, 01:33PM
-
Wed May 20 2015, 01:31PM
-
Tue May 19 2015, 11:17PM
-
Tue May 19 2015, 03:34PM
-
Mon May 18 2015, 01:05PM
-
Sat May 16 2015, 08:24PM
-
Thu May 14 2015, 01:27PM
-
Wed May 13 2015, 05:42PM
-
Wed May 13 2015, 04:39PM
-
Tue May 12 2015, 06:35PM
-
Tue Jul 09 2013, 04:28PM... this conference call took place on July 2nd. 2013... transcript...